Van K. Morris, MD

Articles

Dr. Morris on the Investigation of the Role of ctDNA in Stage II CRC

January 30th 2023

Van K. Morris, MD, discusses the evaluation of circulating tumor as a predictive biomarker for the use of adjuvant chemotherapy in patients with low-risk, stage II colon cancer.

Dr. Morris on the Design of the COBRA Trial in Stage II Colon Cancer

Van K. Morris, MD

September 8th 2020

Van K. Morris, MD, discusses the design of the prospective phase 2/3 NRG-GI005 (COBRA) trial evaluating circulating tumor DNA as a predictive biomarker for adjuvant chemotherapy in patients with colon cancer.

Dr. Morris on the Role of Circulating Tumor DNA in Resected Colon Cancer

Van K. Morris, MD

August 27th 2020

Van K. Morris, MD, discusses the role of circulating tumor DNA in resected colon cancer.

Dr. Morris on the Role of Immunotherapy in Metastatic CRC

Van K. Morris, MD

May 20th 2020

Van K. Morris, MD, discusses the role of immunotherapy in metastatic colorectal cancer.

Dr. Morris on the Role of Immunotherapy in Metastatic CRC

Van K. Morris, MD

May 19th 2020

Van K. Morris, MD, discusses the role of immunotherapy in metastatic colorectal cancer.

Dr. Morris on Treatment Advances Made in BRAF-Mutated mCRC

Van K. Morris, MD

February 25th 2020

Van K. Morris, MD, discusses the recent progress made in the treatment of patients with BRAF-mutated metastatic colorectal cancer.

Dr. Morris on Optimizing CRC Treatment Based on Oligometastatic Status

Van K. Morris, MD

January 25th 2020

Van Morris, MD, discusses research around treatment for patients with unresectable colorectal cancer.

Dr. Van Morris on Nivolumab as a Potential Treatment for Patients With Anal Cancer

Van K. Morris, MD

May 2nd 2016

Van K. Morris, MD, assistant professor of GI Oncology, The University of Texas MD Anderson Cancer Center, discusses a study examining nivolumab (Opdivo) as a potential treatment for patients with anal cancer.